CRISPR Therapeutics
610 Main Street
Cambridge
Massachusetts
02142
United States
Tel: 617-580-9212
Website: http://crisprtx.com/
Email: info@crisprtx.com
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.
268 articles about CRISPR Therapeutics
-
CRISPR Therapeutics to Participate Upcoming May 2023 Investor Conferences
5/2/2023
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in May.
-
The regulatory filing puts the company alongside Vertex and CRISPR, which also await FDA approval for their SCD gene therapy.
-
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
4/13/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17th- 20th, 2023.
-
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
-
In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.
-
CRISPR Therapeutics Announces Departure of Board Member
3/29/2023
CRISPR Therapeutics today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.
-
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
3/27/2023
Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).
-
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
3/14/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.
-
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
-
CRISPR Therapeutics Announces Transition of Chief Financial Officer - March 13, 2023
3/13/2023
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023.
-
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
2/27/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2/21/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - February 8, 2023
2/8/2023
CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in February.
-
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
1/11/2023
CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.
-
The FDA lifted its partial clinical hold on bluebird's experimental sickle cell disease gene therapy for patients younger than 18.
-
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
12/19/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023.
-
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
12/12/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update for both Part A and Part B of the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110®, its wholly-owned allogeneic CAR T cell therapy targeting CD19+ B-cell malignancies.
-
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
12/10/2022
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced an oral, encore presentation of clinical data from patients with sickle cell disease or transfusion-dependent beta-thalassemia treated with the investigational therapy exagamglogene autotemcel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study.
-
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
12/1/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.
-
PACT Pharma shared results of a first-of-its-kind trial using CRISPR technology to swap a gene in a patient’s immune cell to treat solid tumors.